Skip to main content
SpringerLink
Log in
Book cover

Clinically Relevant Resistance in Cancer Chemotherapy pp 27–47Cite as

The Role of Membrane Transporters in Cellular Resistance to Anticancer Nucleoside Drugs

  • Chapter

Part of the book series: Cancer Treatment and Research ((CTAR,volume 112))

Abstract

Physiologic nucleosides and most therapeutic nucleoside analogs do not readily cross plasma membranes by passive diffusion due to their low solubility in lipid bilayers, and their cellular uptake is mediated by integral membrane proteins. Nucleoside transporters serve as the cellular entry point for nucleoside salvage pathways. Some cell types use these pathways exclusively because they lack the ability to synthesize purine and pyrimidine nucleotides. Other cell types use salvage pathways in addition to their de novo synthesis pathways. Nucleotides are key activated intermediates for many essential cellular biosynthetic pathways, including the synthesis of DNA and RNA

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Saier MH. A functional-phylogenetic classification system for transmembrane solute transporters. Microbiol Mol Biol Rev, 64:354–411, 2000.

    Article  PubMed  CAS  Google Scholar 

  2. Ritzel MWL, Ng AML, Yao SYM, et al. Molecular identification and characterization of novel human and mouse concentrative Natnucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (System cib). J Biol Chem, 276:2914–2927, 2001.

    Article  PubMed  CAS  Google Scholar 

  3. Vickers MF, Young JD, Baldwin SA, et al. Nucleoside transporter proteins: emerging targets for drug discovery. Emerging Therapeutic Targets, 4:515–539, 2000.

    Article  CAS  Google Scholar 

  4. Griffiths M, Beaumont N, Yao SY, et al. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nature Med, 3:89–93, 1997.

    Article  PubMed  CAS  Google Scholar 

  5. Ritzel MWL, Yao SYM, Huang MY, et al. Molecular cloning and functional expression of cDNAs encoding a human Na+-nucleoside cotransporter (hCNT1). Amer J Physiol, 272:C707–C714, 1997.

    PubMed  CAS  Google Scholar 

  6. Crawford CR, Patel DH, Naeve C, Belt JA. Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line. J Biol Chem, 273:5288–5293, 1998.

    Article  PubMed  CAS  Google Scholar 

  7. Griffiths M, Yao SYM, Abidi F, et al. Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochem J, 328:739–743, 1997.

    PubMed  CAS  Google Scholar 

  8. Wang J, Su S-F, Dresser MJ, et al. Na+-dependent purine nucleoside transporter from human kidney: cloning and functional characterization. Amer J Physiol, 273:F1058–F1065, 1997.

    PubMed  CAS  Google Scholar 

  9. Ritzel MW, Yao SY, Ng AM, et al. Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Mol Membr Biol, 15:203–211, 1998.

    Article  PubMed  CAS  Google Scholar 

  10. Cass CE. Nucleoside transport. In: Drug Transport in Antimicrobial Therapy and Anticancer Therapy. NH Georgopapadakou (ed.), Marcel Dekker, New York, NY, 1995.

    Google Scholar 

  11. Griffith DA, Jarvis SM. Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta, 1286:153–181, 1996.

    Article  PubMed  CAS  Google Scholar 

  12. Buolamwini JK. Nucleoside transport inhibitors: Structure-activity relationships and potential therapeutic applications. Curr Med Chem, 4:35–66, 1997.

    CAS  Google Scholar 

  13. Wang J, Schaner ME, Thomassen S, et al. Functional and molecular characteristics of Na(+)-dependent nucleoside transporters. Pharm Res, 14:1524–1532, 1997.

    Article  PubMed  CAS  Google Scholar 

  14. Che M, Gatmaitan Z, Arias IM. Ectonucleotidases, purine nucleoside transporter, and function of the bile canalicular plasma membrane of the hepatocyte. FASEB J, 11:101–108, 1997.

    PubMed  CAS  Google Scholar 

  15. Thorn JA, Jarvis SM. Adenosine transporters. Gen Pharmacol, 27:613–620, 1996.

    Article  PubMed  CAS  Google Scholar 

  16. Sundaram M, Yao SY, Ng AM, et al. Chimeric constructs between human and rat equilibrative nucleoside transporters (hENTI and rENT1) reveal hENTI structural domains interacting with coronary vasoactive drugs. J Biol Chem, 273:21519–21525, 1998.

    Article  PubMed  CAS  Google Scholar 

  17. Baldwin SA, Mackey JR, Cass CE, Young JD. Nucleoside transporters: molecular biology and implications for therapeutic development. Mol Med Today, 5:216–224, 1999.

    Article  PubMed  CAS  Google Scholar 

  18. Osses N, Pearson JD, Yudilevich DL, Jarvis SM. Hypoxanthine enters human vascular endothelial cells (ECV 304) via the nitrobenzylthioinosine-insensitive equilibrative nucleoside transporter. Biochem J, 317:843–848, 1996.

    PubMed  CAS  Google Scholar 

  19. Tattersall MH, Slowiaczek P, De Fazio A. Regional variation in human extracellular purine levels. J Lab Clin Med, 102:411–420, 1983.

    PubMed  CAS  Google Scholar 

  20. Vickers MF, Mani RS, Sundaram M, et al. Functional production and reconstitution of the human equilibrative nucleoside transporter (hENTI) in Saccharomyces cerevisiae. Interaction of inhibitors of nucleoside transport with recombinant hENTI and a glycosylation-defective derivative (hENT I/N48Q). Biochem J, 339:21–32, 1999.

    Article  PubMed  CAS  Google Scholar 

  21. Kwong FY, Wu JS, Shi MM, et al. Enzymic cleavage as a probe of the molecular structures of mammalian equilibrative nucleoside transporters. J Biol Chem, 268:22127–22134, 1993.

    PubMed  CAS  Google Scholar 

  22. Coe IR, Griffiths M, Young JD, et al. Assignment of the human equilibrative nucleoside transporter (hENT1) to 6p21.1-p21.2. Genomics, 45:459–460, 1997.

    Article  PubMed  CAS  Google Scholar 

  23. Yao SY, Ng AM, Muzyka WR, et al. Molecular cloning and functional characterization of nitrobenzylthioinosine (NBMPR)-sensitive (es) and NBMPR-insensitive (ei) equilibrative nucleoside transporter proteins (rENT1 and rENT2) from rat tissues. J Biol Chem, 272:28423–28430, 1997.

    Article  PubMed  CAS  Google Scholar 

  24. Boleti H, Coe IR, Baldwin SA, et al. Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells. Neuropharmacol, 36:1167–1179, 1997.

    Article  CAS  Google Scholar 

  25. Ward JL, Sherali A, Mo ZP, Tse CM. Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. ENT2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine. J Biol Chem, 275:8375–8381, 2000.

    Article  PubMed  CAS  Google Scholar 

  26. Hyde RJ, Cass CE, Young JD, Baldwin SA. The ENT family of eukaryote nucleoside transporters: recent advances in the investigation of structure/function relationships and the identification of novel isoforms. Mol Membr Biol, 18:53–63, 2001.

    Article  PubMed  CAS  Google Scholar 

  27. Hamilton SR, Yao SYM, Ingram JC, et al. Sub-cellular distribution and membrane topology of the rat concentrative Natnucleoside co-transporter rCNT1. J Biol Chem, 276:27981–27988, 2001.

    Article  PubMed  CAS  Google Scholar 

  28. Loewen SK, Ng AM, Yao SY, et al. Identification of amino acid residues responsible for the pyrimidine and purine nucleoside specificities of human concentrative Na(+) nucleoside cotransporters hCNTI and hCNT2. J Biol Chem, 274:24475–24484, 1999.

    Article  PubMed  CAS  Google Scholar 

  29. Soler C, Felipe A, Mata JF, et al. Regulation of nucleoside transport by lipopolysaccharide, phorbol esters, and tumour necrosis factor-a in human Blymphocytes. J Biol Chem, 273:26939–26945, 1998.

    Article  PubMed  CAS  Google Scholar 

  30. Kichenin K, Pignede G, Fudelej F, Seman M. CD3 activation induces concentrative nucleoside transport in human T lymphocytes. Eur J Immunol, 30:366–370, 2000.

    Article  PubMed  CAS  Google Scholar 

  31. Vijayalakshmi D, Belt JA. Sodium-dependent nucleoside transport in mouse intestinal epithelial cells. Two transport systems with differing substrate specificities. J Biol Chem, 263:19419–19423, 1988.

    PubMed  CAS  Google Scholar 

  32. Huang QQ, Yao SY, Ritzel MW, et al. Cloning and functional expression of a complementary DNA encoding a mammalian nucleoside transport protein. J Biol Chem, 269:17757–17760, 1994.

    PubMed  CAS  Google Scholar 

  33. Huang QQ, Harvey CM, Paterson AR, et al. Functional expression of Na(+)-dependent nucleoside transport systems of rat intestine in isolated oocytes of Xenopus laevis. Demonstration that rat jejunum expresses the purine-selective system NI (cif) and a second, novel system N3 having broad specificity for purine and pyrimidine nucleosides. J Biol Chem, 268:20613–20619, 1993.

    PubMed  CAS  Google Scholar 

  34. Yao SY, Cass CE, Young JD. Transport of the antiviral nucleoside analogs 3’-azido-3’- deoxythymidine and 2’,3’-dideoxycytidine by a recombinant nucleoside transporter (rCNT) expressed in Xenopus laevis oocytes. Mol Pharmacol, 50:388–393, 1996.

    PubMed  CAS  Google Scholar 

  35. Fang X, Parkinson FE, Mowles DA, et al. Functional characterization of a recombinant sodium-dependent nucleoside transporter with selectivity for pyrimidine nucleosides (cNTlrat) by transient expression in cultured mammalian cells. Biochem J, 317:457–465, 1996.

    PubMed  CAS  Google Scholar 

  36. Crawford CR, Cass CE, Young JD, Belt JA. Stable expression of a recombinant sodium-dependent, pyrimidine-selective nucleoside transporter (CNT1) in a transport-deficient mouse leukemia cell line. Biochem Cell Biol, 76:843–851, 1998.

    Article  PubMed  CAS  Google Scholar 

  37. Mackey JR, Mani RS, Selner M, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res, 58:4349–4357, 1998.

    PubMed  CAS  Google Scholar 

  38. Mackey JR, Yao SY, Smith KM, et al. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst, 91:1876–1881, 1999.

    Article  PubMed  CAS  Google Scholar 

  39. Graham KA, Leithoff J, Coe IR, et al. Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1. Nucleosides Nucleotides Nucleic Acids, 19:415–434, 2000.

    Article  PubMed  CAS  Google Scholar 

  40. Dresser MJ, Gerstin KM, Gray AT, et al. Electrophysiological analysis of the substrate selectivity of a sodium-coupled nucleoside transporter (rCNT1) expressed in Xenopus laevis oocytes. Drug Metabolism and Disposition, 28:1135–1140, 2000.

    PubMed  CAS  Google Scholar 

  41. Che M, Ortiz DF, Arias IM. Primary structure and functional expression of a cDNA encoding the bile canalicular, purine-specific Na+-nucleoside cotransporter. J Biol Chem, 270:13596–13599, 1995.

    Article  PubMed  CAS  Google Scholar 

  42. Yao SY, Ng AM, Ritzel MW, et al. Transport of adenosine by recombinant purine-and pyrimidine-selective sodium/nucleoside cotransporters from rat jejunum expressed in Xenopus laevis oocytes. Mol Pharmacol, 50:1529–1535, 1996.

    PubMed  CAS  Google Scholar 

  43. Roovers KI, Meckling-Gill KA. Characterization of equilibrative and concentrative Na+- dependent (cif) nucleoside transport in acute promyelocytic leukemia NB4 cells. J Cell Physiol, 166:593–600, 1996.

    Article  PubMed  CAS  Google Scholar 

  44. Belt JA, Harper EH, Byl JA, Noel LD. Sodium-dependent nucleoside transport in human myeloid leukemic cell lines and freshly isolated myeloblasts. Proc Amer Assoc Cancer Res, 33:20, 1992.

    Google Scholar 

  45. Belt JA, Marina NM, Phelps DA, Crawford CR. Nucleoside transport in normal and neoplastic cells. Adv Enzyme Regul, 33:235–252, 1993.

    Article  PubMed  CAS  Google Scholar 

  46. Flanagan SA, Mecklinggill KA. Characterization of a novel Na+ dependent, guanosine specific, nitrobenzylthioinosine sensitive transporter in acute promyelocytic leukemia cells. J Biol Chem, 272:18026–18032, 1997.

    Article  PubMed  CAS  Google Scholar 

  47. Paterson AR, Gati WP, Vijayalakshmi D, et al. Inhibitor-sensitive, Na(+)-linked transport of nucleoside analogs in leukemia cells from patients. Proc Amer Assoc Cancer Res, 34:A84, 1993.

    Google Scholar 

  48. Wiley JS, Cebon JS, Jamieson GP, et al. Assessment of proliferative responses to granulocyte-macrophage colony-stimulating factor (GM-CSF) in acute myeloid leukaemia using a fluorescent ligand for the nucleoside transporter. Leukemia, 8:181–185, 1994.

    PubMed  CAS  Google Scholar 

  49. Smith CL, Pilarski LM, Egerton ML, Wiley JS. Nucleoside transport and proliferative rate in human thymocytes and lymphocytes. Blood, 74:2038–2042, 1989.

    PubMed  CAS  Google Scholar 

  50. Wiley JS, Snook MB, Jamieson GP. Nucleoside transport in acute leukaemia and lymphoma: close relation to proliferative rate. Br J Haematol, 71:203–207, 1989.

    Article  PubMed  CAS  Google Scholar 

  51. Mackey JR, Jennings LL, Clarke ML, et al. Immunohistochemical variation of human equilibrative nucleoside transporter 1 (hENT1) protein in primary breast cancers. Clin Cancer Res, 1:110–116, 2002.

    Google Scholar 

  52. Gati WP, Paterson AR, Belch AR, et al. Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC). Leuk Lymphoma, 32:45–54, 1998.

    PubMed  CAS  Google Scholar 

  53. Wright AM, Gati WP, Paterson AR. Enhancement of retention and cytotoxicity of 2- chlorodeoxyadenosine in cultured human leukemic lymphoblasts by nitrobenzylthioinosine, an inhibitor of equilibrative nucleoside transport. Leukemia, 14:52–60, 2000.

    Article  PubMed  CAS  Google Scholar 

  54. Chen R, Nelson JA. Role of organic cation transporters in the renal secretion of nucleosides. Biochem Pharmacol, 60:215–219, 2000.

    Article  PubMed  CAS  Google Scholar 

  55. Cohen A, Ullman B, Martin DW, Jr. Characterization of a mutant mouse lymphoma cell with deficient transport of purine and pyrimidine nucleosides. J Biol Chem, 254:112–116, 1979.

    PubMed  CAS  Google Scholar 

  56. Cass CE, Kolassa N, Uehara Y, et al. Absence of binding sites for the transport inhibitor nitrobenzylthioinosine on nucleoside transport-deficient mouse lymphoma cells. Biochim Biophys Acta, 649:769–777, 1981.

    Article  PubMed  CAS  Google Scholar 

  57. Ullman B, Coons T, Rockwell S, McCartan K. Genetic analysis of 2’,3’-dideoxycytidine incorporation into cultured human T lymphoblasts. J Biol Chem, 263:12391–12396, 1988.

    PubMed  CAS  Google Scholar 

  58. Ullman B. Dideoxycytidine metabolism in wild type and mutant CEM cells deficient in nucleoside transport or deoxycytidine kinase. Adv Exp Med Biol, 253B:415–420, 1989.

    Article  PubMed  CAS  Google Scholar 

  59. Hoffman J. Murine erythroleukemia cells resistant to periodate-oxidized adenosine have lowered levels of nucleoside transporter. Adv Exp Med Biol, 309A:443–446, 1991.

    PubMed  CAS  Google Scholar 

  60. Sobrero AF, Handschumacher RE, Bertino JR. Highly selective drug combinations for human colon cancer cells resistant in vitro to 5-fluoro-2’-deoxyuridine. Cancer Res, 45:3161–3163, 1985.

    PubMed  CAS  Google Scholar 

  61. Ellison RR, Holland JF, Weil M, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood, 32:507–523, 1968.

    PubMed  CAS  Google Scholar 

  62. Solimando DA, Bressler LR, Kintzel PE, Geraci M. Drug Information Handbook for Oncology. Lexi-Comp Inc., Hudson (Cleveland), Ohio, 1999.

    Google Scholar 

  63. Allegra CJ, Grem JL. Antimetabolites. In: Cancer: Principles and Practice of Oncology. 5th edition, VT DeVita Jr (ed.), Lippincott-Raven, Philadelphia, PA, 1997.

    Google Scholar 

  64. Skeel RT. Handbook of Cancer Chemotherapy, 5th edition, Lippincott Williams and Wilkins, New York, NY, 1999.

    Google Scholar 

  65. Wiley JS, Jones SP, Sawyer WH. Cytosine arabinoside transport by human leukaemic cells. Eur J Cancer Clin Oncol, 19:1067–1074, 1983.

    Article  PubMed  CAS  Google Scholar 

  66. Yoshida S, Yamada M, Masaki S. Inhibition of DNA polymerase a and r3 of calf thymus by 1–13-D-arabinofuranosylcytosine 5’ triphosphate. Biochim Biophys Acta, 477:144–150, 1977.

    Article  PubMed  CAS  Google Scholar 

  67. Dijkwel PA, Wanka F. Enhanced release of nascent single strands from DNA synthesized in the presence of arabinosylcytosine. Biochim Biophys Acta, 520:461–471, 1978.

    Article  PubMed  CAS  Google Scholar 

  68. Gunji H, Kharbanda S, Kufe D. Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1–0-D-arabinofuranosylcytosine. Cancer Res, 51:741–743, 1991.

    PubMed  CAS  Google Scholar 

  69. Kufe D, Spriggs D, Egan EM, Munroe D. Relationships among ara-CTP pools, formation of (ara-C)DNA, and cytotoxicity of human leukemic cells. Blood, 64:54–58, 1984.

    PubMed  CAS  Google Scholar 

  70. Rustum YM, Preisler HD. Correlation between leukemic cell retention of l-ß-Darabinofuranosylcytosine 5’-triphosphate and response to therapy. Cancer Res, 39:42–49, 1979.

    PubMed  CAS  Google Scholar 

  71. Ho DHW, Frei E. Clinical pharmacology of 1–13-D-arabinofuranosyl cytosine. Clin Pharmacol Ther, 12:944–954, 1971.

    PubMed  CAS  Google Scholar 

  72. Wiley JS, Jones SP, Sawyer WH, Paterson AR. Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J Clin Invest, 69:479–489, 1982.

    Article  PubMed  CAS  Google Scholar 

  73. Wiley JS, Woodruff RK, Jamieson GP, et al. Cytosine arabinoside in the treatment of Tcell acute lymphoblastic leukemia. Aust N Z J Med, 7;17:379–386, 1987.

    Google Scholar 

  74. Wiley JS, Taupin J, Jamieson GP, et al. Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. J Clin Invest, 75:632–642, 1985.

    Article  PubMed  CAS  Google Scholar 

  75. Gati WP, Paterson AR, Larratt LM, et al. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. Blood, 90:346–353, 1997.

    PubMed  CAS  Google Scholar 

  76. White JC, Rathmell JP, Capizzi RL. Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells. J Clin Invest, 79:380–387, 1987.

    Article  PubMed  CAS  Google Scholar 

  77. Jamieson GP, Snook MB, Wiley JS. Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells. Leuk Res, 14:475–479, 1990.

    Article  PubMed  CAS  Google Scholar 

  78. Capizzi RL, Yang JL, Cheng E, et al. Alteration of the pharmacokinetics of high-dose araC by its metabolite, high ara-U in patients with acute leukemia. J Clin Oncol, 1:763–771, 1983.

    PubMed  CAS  Google Scholar 

  79. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood, 87:1710–1717, 1996.

    PubMed  CAS  Google Scholar 

  80. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood, 88:2841–2851, 1996.

    PubMed  CAS  Google Scholar 

  81. Greyer MR, Kopecky KJ, Coltman CA, et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol, 30:457–459, 1988.

    Google Scholar 

  82. Cheson BD. New prospects in the treatment of indolent lymphomas with purine analogues. Cancer J, 4:S27–S36, 1998.

    Google Scholar 

  83. Leiby JM, Snider KM, Kraut EH, et al. Phase II trial of 9–13-D-arabinofuranosy1–2- fluoroadenine 5’-monophosphate in non-Hodgkin’s lymphoma: prospective comparison of response with deoxvcvtidine kinase activity. Cancer Res, 47:2719–2722. 1987.

    PubMed  CAS  Google Scholar 

  84. Plunkett W, Saunders PP. Metabolism and action of purine nucleoside analogs. Pharmacol Ther, 49:239–268, 1991.

    Article  PubMed  CAS  Google Scholar 

  85. Cheson BD. Miscellaneous chemotherapeutic agents. In: Cancer: Principles and Practice of Oncology, 5th edition, VT DeVita Jr (ed.), Lippincott-Raven, Philadelphia, PA, 1997.

    Google Scholar 

  86. Ross SR, McTavish D, Faulds D. Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy. Drugs, 45:737–759, 1993.

    Article  PubMed  CAS  Google Scholar 

  87. Plunkett W, Chubb S, Alexander L, Montgomery JA. Comparison of the toxicity and metabolism of 9-I3-D-arabinofuranosy1–2-fluoroadenine and 9-ft-D- arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res, 40:2349–2355, 1980.

    PubMed  CAS  Google Scholar 

  88. Huang P, Plunkett W. Fludarabine-and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol, 36:181–188, 1995.

    Article  PubMed  CAS  Google Scholar 

  89. Huang P, Plunkett W. Action of 9-ft-D-arabinofuranosy1–2-fluoroadenine on RNA metabolism. Mol Pharmacol, 39:449–455, 1991.

    PubMed  CAS  Google Scholar 

  90. King KM, Cass CE. Membrane transport of 2-chloro-2’-deoxyadenosine and 2-chloro-2’- arabinofluoro-2’-deoxyadenosine is required for cytotoxicity. Proc Amer Assoc Cancer Res, 35:A3436, 1994.

    Google Scholar 

  91. Avery TL, Rehg JE, Lumm WC, et al. Biochemical pharmacology of 2chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice. Cancer Res, 49:4972–4978, 1989.

    PubMed  CAS  Google Scholar 

  92. Heinemann V, Xu YZ, Chubb S, et al. Cellular elimination of 2’,2’-difluorodeoxycytidine 5’-triphosphate: a mechanism of self-potentiation. Cancer Res, 52:533–539, 1992.

    PubMed  CAS  Google Scholar 

  93. Baker CH, Banzon J, Bollinger JM, et al. 2’-Deoxy-2’-methylenecytidine and 2’-deoxy2’,2’-difluorocytidine 5’- diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem, 34:1879–1884, 1991.

    Article  PubMed  CAS  Google Scholar 

  94. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2’,2’-difluorodeoxycytidine and 1-beta-Darabinofuranosylcytosine. Cancer Res, 48:4024–4031, 1988.

    PubMed  CAS  Google Scholar 

  95. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol, 17:485–493, 1999.

    PubMed  CAS  Google Scholar 

  96. Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol, 55:1091–1097, 1998.

    Article  PubMed  CAS  Google Scholar 

  97. Schmoll H-J, Buchele T, Grothey A, Dempke W. Where do we stand with 5-fluorouracil? Semin Oncol, 26:589–605, 1999.

    PubMed  CAS  Google Scholar 

  98. Jennings LL, Hao C, Cabrita MA, et al. Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENTI and hENT2) in the central nervous system. Neuropharmacol, 40:722–731, 2001.

    Article  CAS  Google Scholar 

  99. Ahmad I, Al-Katib AM, Beck FW, Mohammad RM. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2chlorodeoxyadenosine: case report. Clin Cancer Res, 6:1328–1332, 2000.

    PubMed  CAS  Google Scholar 

  100. Beck FW, Al-Katib AM, Ahmad I, et al. Bryostatin 1-induced modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells. Int J Mol Med, 5:341–347, 2000.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Experimental Oncology, Canada

    Marilyn L. Clarke, John R. Mackey & Carol E. Cass

  2. Department of Medicine, Cross Cancer Institute, Edmonton, Alberta, Canada

    John R. Mackey

  3. School of Biochemistry and Molecular Biology, University of Leeds, Leeds, UK

    Stephen A. Baldwin

  4. Department of Physiology, University of Alberta, Edmonton, Alberta, Canada

    James D. Young

  5. Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada

    Carol E. Cass

  6. Department of Oncology, University of Alberta, Edmonton, Alberta, Canada

    John R. Mackey & Carol E. Cass

Authors
  1. Marilyn L. Clarke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John R. Mackey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephen A. Baldwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James D. Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carol E. Cass
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. MD Anderson Cancer Center, Houston, Texas, USA

    Borje Andersson M.D., Ph.D

  2. Cross Cancer Institute, Edmonton, Alberta, Canada

    David Murray Ph.D

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Clarke, M.L., Mackey, J.R., Baldwin, S.A., Young, J.D., Cass, C.E. (2002). The Role of Membrane Transporters in Cellular Resistance to Anticancer Nucleoside Drugs. In: Andersson, B., Murray, D. (eds) Clinically Relevant Resistance in Cancer Chemotherapy. Cancer Treatment and Research, vol 112. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1173-1_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-1173-1_2

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5428-4

  • Online ISBN: 978-1-4615-1173-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation